Coronavirus LIVE Updates: Punjab Govt Extends Night Curfew Till Jan 1 to Curb Virus Spread
Coronavirus LIVE Updates: Punjab Govt Extends Night Curfew Till Jan 1 to Curb Virus Spread
Coronavirus LIVE Updates: India on Thursday recorded 29,398 new COVID-19 infections and 414 fresh fatalities. While the total cases rose to 97,96,770, the death toll mounted to 1,42,186. Meanwhile, the total number of active cases stood at 3,63,749, said the data shown by the Union Health Ministry.

Coronavirus LIVE Updates: Due to the continuous surge in Covid-19 cases in Punjab, Chief Minister Captain Amarinder Singh has announced the extension of night curfew across the state from 10 pm to 5 am till 1 January next year. Meanwhile, India on Thursday recorded 29,398 new COVID-19 infections and 414 fresh fatalities. While the total cases rose to 97,96,770, the death toll mounted to 1,42,186. The total number of active cases stood at 3,63,749, said the data shown by the Union Health Ministry. Besides, the country discharged 37,528 patients in the last 24 hours. India has, so far, reported 92,90,834 discharges.

The number of people who have recuperated from the disease surged to 92,90,834, pushing the national recovery rate to94.84 per cent. The COVID-19 case fatality rate stands at 1.45 per cent. The COVID-19 active caseload remained below 4 lakh for the fifth consecutive day.

In a grim milestone, the United States recorded over 3,000 American COVID-19 deaths in a single day, surpassing the fatalities on D-Day or 9/11. The crisis across the country is pushing medical centers to the breaking point and leaving staff members and public health officials burned out and plagued by tears and nightmares.

Meanwhile, a US government advisory panel has recommended emergency approval for the Pfizer-BioNTech coronavirus vaccine, underlining that the shot’s potential benefits outweigh its risks. Thus, paving the way for the agency to authorize the shot for a nation that has lost more than 285,000 lives to COVID-19.

The FDA is widely expected to authorize the vaccine, developed with German partner BioNTech SE, for emergency use in the United States within days. Distribution and inoculations are expected to begin almost immediately thereafter.

Pfizer had asked that the two-dose vaccine be approved for use in people aged 16 to 85. Several advisory panel members discussed whether 16 and 17-year-olds should be included in the recommendation because the risk to these individuals is low, and the evidence in the trial was scant.

Read all the Latest India News here

What's your reaction?

Comments

https://kapitoshka.info/assets/images/user-avatar-s.jpg

0 comment

Write the first comment for this!